1.Gallo D, Young JTF, Fourtounis J, Martino G, Álvarez-Quilón A, Bernier C, Duffy NM, Papp R, Roulston A, Stocco R, Szychowski J, Veloso A, Alam H, Baruah PS, Fortin AB, Bowlan J, Chaudhary N, Desjardins J, Dietrich E, Fournier S, Fugère-Desjardins C, Goullet de Rugy T, Leclaire ME, Liu B, Bhaskaran V, Mamane Y, Melo H, Nicolas O, Singhania A, Szilard RK, Tkáč J, Yin SY, Morris SJ, Zinda M, Marshall CG, Durocher D. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20. PMID: 35444283; PMCID: PMC9046089..
2.Zheng X, Chen L, Liu W, Zhao S, Yan Y, Zhao J, Tian W, Wang Y. CCNE1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis. Hereditas. 2023 Mar 24;160(1):13. doi: 10.1186/s41065-023-00273-0. PMID: 36964635; PMCID: PMC10037856.
3.House NC, Brown VE, Chen M, Yuan L, Moore SL, Guo J, Choi YJ, Muthuswamy L, Ribich S, Ramsden P, Faia KL. Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer Res. 2025 Apr 3;85(7):1297-1309. doi: 10.1158/0008-5472.CAN-24-2360. PMID: 39945650; PMCID: PMC11967718.